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DrAntoon Lerut (Leuven, Belgium). Thank you, Dr Li, for this
excellent presentation on an interesting topic, and thank you also
for providing me with the manuscript well in advance.
In 1994, Dr Akiyama from Tokyo published in the Annals of
Surgery his landmark report on radical lymph node dissection
for cancer of the thoracic esophagus. His publication focused on
a meticulous analysis of the pattern of lymph node spread in a se-
ries of 290 patients who all underwent 3-FL during a period span-
ning 20 years. Your presentation, now 20 years later, has the
advantage that it included a very large cohort of 1361 patients
within a short period of barely 5 years, making, of course,
a much larger and more coherent group.
In the report by Akiyama, the incidence of cervical lymph node
involvement was 38% overall, and for lower esophageal tumors,
was as much as 27%, indicating that, indeed, as you mentioned
in your report, there is in your study material a bias in the sense
that you performed 3-FL in only 21% of your patients. Moreover,
those were the patients who had on CTor ultrasound scan, a suspi-
cion of positive lymph nodes in the neck.
I alsowould like to quote another publication, again from Japan,
by Dr Nishimaki, on 3-FL, but this time specifically for early T1
tumors. In that report, 57% of the patients had positive nodes, of
which as much as 16% were, again, in the cervical region.
Within this context, I have 3 questions. First, the purpose of
your study was to obtain useful information to guide lymphade-
nectomy. Given the probably greater incidence of positive lymph
nodes in the neck than you actually reported, would you consider
performing systematic biopsy and frozen section analysis of the in-
trathoracic high paratracheal lymph node chain, and, in case of
a positive report, would you then perform systematic cervical lym-
phadenectomy, in addition to the thoracic and abdominal compart-
ments, irrespective of the tumor location and negative CT or
ultrasound findings?
Dr Li. Thank you for your question, Professor Lerut.
This was a retrospective study, and we included all the patients
who had undergone radical lymphadenectomy. Obviously, there
was a selection bias in our study. At present, we cannot conduct
cervical lymphadenectomy unselectively because of surgeon pref-
erence and in consideration of the high incidence of postoperative
complications. Thus, the bias was present. However, it could be
true that we could use the intraoperative information to select pa-
tients for cervical lymphadenectomy individually.
Dr Lerut. In the future?
Dr Li. Yes, and we will work on this aspect.
Dr Lerut. Thank you.
My second question—you did not speak on the number of in-
volved lymph nodes. Is there a correlation between the number
of positive intrathoracic lymph nodes and, again, the probability
of having lymph node involvement in the cervical region? Further-
more, you showed that in T1 tumors you had an approximately
20% incidence of overall positive lymph node involvement. DidThe Journal of Thoracic and Cayou have an opportunity to study the subdivision of the T1b tumors
in submucosal area (sm)1, sm2, sm3? That correlates, of course,
with the whole discussion on the indications for endoluminal
therapies.
Dr Li. It is true a relationship exists between the number of pos-
itive lymph nodes in the mediastinum and metastasis in the cervi-
cal region in our analysis. Because of our selection bias for the
patients who underwent 3-FL, more positive lymph nodes were
usually found in the patients with an advanced tumor stage.
Regarding the subclassification of the T1b tumors, actually we
only just finished this work last month. The proportion of superfi-
cial cancer was not large in our center, and it was about 15% in
total. The incidence of metastases for sm1 and sm2 tumors was
about 20%, and it was about 38% for the sm3 tumors.
Dr Lerut. So sm1 and sm2 was 20% overall?
Dr Li.Yes, it was about 20% for sm1 and sm2 overall and about
30% for T1b tumors overall.
Dr Lerut. My third question is a more general question. The
purpose of your study was also to obtain useful information for fu-
ture clinical trials. In the United States and in Europe as well, most
patients with the finding of 1 or more positive nodes on clinical
staging currently will be treated with induction chemotherapy or
chemoradiotherapy. From your report, it appears that only a small
minority of patients received induction therapy. Thus, from your
results and given the well-known negative prognostic effect of
lymph node involvement, which was present in more than one
half of your patients, are you considering to opt for induction ther-
apy for patients who, on clinical staging, have positive nodes or do
you believe that primary surgery with radical lymphadenectomy is
to be preferred?
I would like to thank the Association for the privilege to discuss
this highly interesting presentation.
Dr Li. In fact, induction therapy before surgery, or neoadjuvant
chemotherapy or chemoradiotherapy, was not usually performed
in our institution. Only 30 patients received chemotherapy or ra-
diotherapy before surgery. However, in fact, what they received
could not be regard as induction therapy or neoadjuvant therapy,
because some of these patients underwent surgery owing to recur-
rence after radiotherapy, and some underwent surgery because
they refused the chemotherapy after 1 or 2 cycles; they had
changed their minds and requested surgery. Thus, we excluded
these patients from the present study, and the proportion of these
patients was small.
Dr Lerut. But would you in the future consider an increase in
the indications for induction therapy?
Dr Li. Neoadjuvant therapy might be of benefit, and we will
change our treatment strategy according to the findings of future
clinical trials. But, at present, surgeons and most of the patients
in our institution prefer surgery as the first choice.
Dr Lerut. Clever patients.
Dr Haiquan Chen (Shanghai, China). If I might answer the
question, for squamous cell carcinoma, no data are available to
show that neoadjuvant chemotherapy has a positive result. So, per-
haps we will try that. We have a lot of patients. Perhaps we can ini-
tiate that trial.
Speaking of the sm1, sm2, and sm3, that is a new concept. We
asked the pathologist to go back and review that in all the patho-
logic specimens. Our results on that study will come out soon.rdiovascular Surgery c Volume 144, Number 4 785
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SDr Lerut. We are looking forward to that study next year.
DrChen. Sm1 and sm2, that was about 20%, with no difference
in sm1, sm2. However, sm3 was 38%. That was high.
Dr Nasser K. Altorki (New York, NY). I enjoyed your
presentation.
I just want to clarify something. When you speak about the par-
atracheal lymph nodes, that constitutes multiple stations of lymph
nodes. What specific nodal stations did you actually dissect in the
paratracheal area? Was that 2, 3, or 4?
Dr Chen (Shanghai, China). Yes, there were several. Both bi-
lateral recurrent nerves, specifically that level, bilateral recurrent
nerves.
Dr Altorki. Do you dissect 2 or 4?786 The Journal of Thoracic and Cardiovascular SurgDr Chen. For Ivor-Lewis, we do bilateral; the lymph nodes
along the right recurrent nerve and left recurrent nerve were all
removed.
Dr Altorki. Yes, but you did not dissect anything in front of the
trachea.
Dr Chen. Yes, because metastasis in this region was rare ac-
cording to our data, we did not routinely remove the lymph nodes
anterior to the trachea.
Dr Altorki. I agree. I just wanted to make sure. I think it is im-
portant that when you state paratracheal that you actually specify
the precise nodal station, because it could be commonly understood
to include the nodes behind the cava and in front of the trachea.
Dr Chen. Yes, that is true.ery c October 2012
